{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:18:00Z","timestamp":1793459880324,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gaucher disease (GD) is a rare, autosomal recessive lysosomal storage disorder that adversely affects life expectancy and health-related quality of life (HRQOL). Although HRQOL questionnaires are available for type 1 GD, they are not suitable for patients with the neuronopathic types 2 and 3 GD who have neurological symptoms that develop during early childhood or adolescence. Here we report the development of a language-validated HRQOL questionnaire specifically for patients with neuronopathic types 2 and 3 GD in Japan, which is the first step toward HRQOL questionnaire provision for all types of GD in the future.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In February and March 2021, semi-structured interviews were conducted by the authors (supported by qualified interviewers) with patients and\/or their caregivers (for patients\u2009&lt;\u200916\u00a0years old) who were recruited from a Japanese patient association, the Association of Gaucher Disease Patients in Japan. Qualitative analysis of interview transcripts was used to identify major themes and key topics within those themes. Hierarchical cluster analysis and co-occurrence network analysis were performed to map relationships between commonly occurring words. The study is registered at the UMIN Clinical Trials Registry (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.umin.ac.jp\/ctr\/index.htm\">https:\/\/www.umin.ac.jp\/ctr\/index.htm<\/jats:ext-link> [UMIN000042872]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Three main themes emerged from qualitative analysis: treatment status, patient burden, and social support systems. Key topics within each theme included hearing impairment, visual impairment, difficulty swallowing, difficulty speaking, involuntary movement of extremities, epileptic seizures, and body aches (treatment status); anxiety about symptoms, difficulty with exercise and work, anxiety about continuing treatment, anxiety about going out, and tiredness from hospital visit or treatment (patient burden); and dissatisfaction about government service, lack of social support, and information exchange in the patient association (social support systems). Commonly used words and the relationships between words identified through the hierarchical cluster and co-occurrence network analyses supported these themes and topics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The themes and topics identified in this analysis were specific to patients with types 2 and 3 GD and will be used to inform the development of a HRQOL questionnaire specifically for patients with all GD types.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02429-z","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T11:06:59Z","timestamp":1658228819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Qualitative analysis of patient interviews on the burden of neuronopathic Gaucher disease in Japan"],"prefix":"10.1186","volume":"17","author":[{"given":"Yuta","family":"Koto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Lissa","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-6709","authenticated-orcid":false,"given":"Norio","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"2429_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/10245332.2016.1240391","volume":"22","author":"L Nalysnyk","year":"2017","unstructured":"Nalysnyk L, Rotella P, Simeone JC, Hamed A, Weinreb N. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2017;22:65\u201373.","journal-title":"Hematology"},{"key":"2429_CR2","first-page":"1189","volume-title":"Williams hematology","author":"S Revel-Vilk","year":"2021","unstructured":"Revel-Vilk S, Szer J, Zimran A. Chapter 72: Gaucher disease and related lysosomal storage diseases. In: Kaushansky K, Prchal JT, Burns LJ, Lichtman MA, Levi M, Linch DC, editors. Williams hematology. 10th ed. New York: McGraw Hill; 2021. p. 1189\u2013202.","edition":"10"},{"key":"2429_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","volume":"83","author":"E Sidransky","year":"2004","unstructured":"Sidransky E. Gaucher disease: complexity in a \u201csimple\u201d disorder. Mol Genet Metab. 2004;83:6\u201315.","journal-title":"Mol Genet Metab"},{"key":"2429_CR4","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000;160:2835\u201343.","journal-title":"Arch Intern Med"},{"key":"2429_CR5","volume-title":"Gaucher's disease clinical practice guidelines [Japanese]","author":"Japan Society of Congenital Metabolic Disorders","year":"2021","unstructured":"Japan Society of Congenital Metabolic Disorders. Gaucher\u2019s disease clinical practice guidelines [Japanese]. Tokyo: Shindan To Chiryo Sha; 2021."},{"key":"2429_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ymgme.2021.05.004","volume":"133","author":"Y Koto","year":"2021","unstructured":"Koto Y, Sakai N, Lee Y, Kakee N, Matsuda J, Tsuboi K, et al. Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: a nationwide survey in Japan. Mol Genet Metab. 2021;133:277\u201388.","journal-title":"Mol Genet Metab"},{"key":"2429_CR7","unstructured":"Ida H. Gaucher disease\/inherited metabolic disease syndrome part 2. 2nd ed. [Japanese]. Nippon Rinsho (Supplement). 2012; 465\u20137."},{"key":"2429_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/ajh.24957","volume":"93","author":"A Zimran","year":"2018","unstructured":"Zimran A, Belmatoug N, Bembi B, Deegan P, Elstein D, Fernandez-Sasso D, et al. Demographics and patient characteristics of 1209 patients with Gaucher disease: descriptive analysis from the Gaucher Outcome Survey (GOS). Am J Hematol. 2018;93:205\u201312.","journal-title":"Am J Hematol"},{"key":"2429_CR9","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/ajmg.a.33527","volume":"152A","author":"W Packman","year":"2010","unstructured":"Packman W, Crosbie TW, Behnken M, Eudy K, Packman S. Living with Gaucher disease: emotional health, psychosocial needs and concerns of individuals with Gaucher disease. Am J Med Genet A. 2010;152A:2002\u201310.","journal-title":"Am J Med Genet A"},{"key":"2429_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10897-013-9579-1","volume":"22","author":"R Freedman","year":"2013","unstructured":"Freedman R, Sahhar M, Curnow L, Lee J, Peters H. Receiving enzyme replacement therapy for a lysosomal storage disorder: a preliminary exploration of the experiences of young patients and their families. J Genet Couns. 2013;22:517\u201332.","journal-title":"J Genet Couns"},{"key":"2429_CR11","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/jgc4.1421","volume":"30","author":"EC Lisi","year":"2021","unstructured":"Lisi EC, Ali N. Opinions of adults affected with later-onset lysosomal storage diseases regarding newborn screening: a qualitative study. J Genet Couns. 2021;30:1544\u201358.","journal-title":"J Genet Couns"},{"key":"2429_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13023-015-0280-3","volume":"10","author":"NJ Weinreb","year":"2015","unstructured":"Weinreb NJ, Finegold DN, Feingold E, Zeng Z, Rosenbloom BE, Shankar SP, et al. Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3). Orphanet J Rare Dis. 2015;10:64.","journal-title":"Orphanet J Rare Dis"},{"key":"2429_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13023-021-02163-y","volume":"17","author":"D Elstein","year":"2022","unstructured":"Elstein D, Belmatoug N, Deegan P, G\u00f6ker-Alpan \u00d6, Hughes DA, Schwartz IVD, et al. Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials. Orphanet J Rare Dis. 2022;17:9.","journal-title":"Orphanet J Rare Dis"},{"key":"2429_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13023-020-01544-z","volume":"15","author":"T Dinur","year":"2020","unstructured":"Dinur T, Istaiti M, Frydman D, Becker-Cohen M, Szer J, Zimran A, et al. Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease. Orphanet J Rare Dis. 2020;15:284.","journal-title":"Orphanet J Rare Dis"},{"key":"2429_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s41687-019-0140-3","volume":"3","author":"M Harrington","year":"2019","unstructured":"Harrington M, Hareendran A, Skalicky A, Wilson H, Clark M, Mikl J. Assessing the impact on caregivers caring for patients with rare pediatric lysosomal storage diseases: development of the Caregiver Impact Questionnaire. J Patient Rep Outcomes. 2019;3:44.","journal-title":"J Patient Rep Outcomes"},{"key":"2429_CR16","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s11136-018-1829-0","volume":"27","author":"CB Terwee","year":"2018","unstructured":"Terwee CB, Prinsen CAC, Chiarotto A, Westerman MJ, Patrick DL, Alonso J, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. Qual Life Res. 2018;27:1159\u201370.","journal-title":"Qual Life Res"},{"key":"2429_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","volume":"114","author":"K Weiss","year":"2015","unstructured":"Weiss K, Gonzalez A, Lopez G, Pedoeim L, Groden C, Sidransky E. The clinical management of Type 2 Gaucher disease. Mol Genet Metab. 2015;114:110\u201322.","journal-title":"Mol Genet Metab"},{"key":"2429_CR18","doi-asserted-by":"crossref","unstructured":"Shemesh E, Deroma L, Bembi B, Deegan P, Hollak C, Weinreb NJ, et al. Enzyme replacement and substrate reduction therapy for Gaucher disease. Cochrane Database Syst Rev. 2015. CD010324.","DOI":"10.1002\/14651858.CD010324.pub2"},{"key":"2429_CR19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/ped.12339","volume":"56","author":"N Yotani","year":"2014","unstructured":"Yotani N, Ishiguro A, Sakai H, Ohfuji S, Fukushima W, Hirota Y. Factor-associated caregiver burden in medically complex patients with special health-care needs. Pediatr Int. 2014;56:742\u20137.","journal-title":"Pediatr Int"},{"key":"2429_CR20","doi-asserted-by":"crossref","unstructured":"Koto Y, Ueki S, Yamakawa M, Sakai N. Experiences of patients with lysosomal storage disorders who are receiving enzyme-replacement therapy and the experiences of their family members: a qualitative systematic review. JBI Evid Synth. 2022;20:1474\u2013510.","DOI":"10.11124\/JBIES-21-00074"},{"key":"2429_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ymgme.2021.02.005","volume":"132","author":"EI Ginns","year":"2021","unstructured":"Ginns EI, Ryan E, Sidransky E. Gaucher disease in the COVID-19 pandemic environment: the good, the bad and the unknown. Mol Genet Metab. 2021;132:213\u20134.","journal-title":"Mol Genet Metab"},{"key":"2429_CR22","unstructured":"Act on Medical Care for Patients with Intractable Diseases (Act No. 50 of May 30, 2014) [Japanese]. https:\/\/www.mhlw.go.jp\/web\/t_doc?dataId=80ab4067&dataType=0&pageNo=1. Accessed 2 Feb 2022."},{"key":"2429_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.12968\/bjon.2006.15.6.20681","volume":"15","author":"A Milligan","year":"2006","unstructured":"Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs. 2006;15:330\u20133.","journal-title":"Br J Nurs"},{"key":"2429_CR24","unstructured":"The 475th meeting minutes of the Central Social Insurance Medical Council (February 10, 2021) [Japanese]. https:\/\/www.mhlw.go.jp\/stf\/shingi2\/0000205879_00118.html. Accessed 2 Feb 2022."},{"key":"2429_CR25","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/cch.12767","volume":"46","author":"A Matsuzawa","year":"2020","unstructured":"Matsuzawa A, Shiroki Y, Arai J, Hirasawa A. Care coordination for children with medical complexity in Japan: caregivers\u2019 perspectives. Child Care Health Dev. 2020;46:436\u201344.","journal-title":"Child Care Health Dev"},{"key":"2429_CR26","first-page":"137","volume":"53","author":"K Higuchi","year":"2017","unstructured":"Higuchi K. A two-step approach to quantitative content analysis: KH coder tutorial using Anne of Green Gables (Part II). Ritsumeikan Soc Sci Rev. 2017;53:137\u201347.","journal-title":"Ritsumeikan Soc Sci Rev"},{"key":"2429_CR27","first-page":"77","volume":"52","author":"K Higuchi","year":"2016","unstructured":"Higuchi K. A two-step approach to quantitative content analysis: KH coder tutorial using Anne of Green Gables (Part I). Ritsumeikan Soc Sci Rev. 2016;52:77\u201391.","journal-title":"Ritsumeikan Soc Sci Rev"}],"updated-by":[{"DOI":"10.1186\/s13023-023-02659-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000}}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02429-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02429-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02429-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T18:08:43Z","timestamp":1679681323000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02429-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2429"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02429-z","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13023-023-02659-9","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"assertion":[{"value":"14 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13023-023-02659-9","URL":"https:\/\/doi.org\/10.1186\/s13023-023-02659-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and informed consent form were approved on January 13, 2021 (No. 20342) by Osaka University Clinical Research Review Committee. Written informed consent was obtained by patients or their proxies. This study was conducted in accordance with the protocol, the Declaration of Helsinki, Guidelines for Good Pharmacoepidemiology Practices by the International Society of Pharmacoepidemiology, and Japanese regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YK, AN, and NS have received research funding from Takeda Pharmaceutical Company Limited (Takeda, hereafter) and have served as consultants and on speakers\u2019 bureaus for Takeda. SN has served as a consultant for Takeda. MO and ALH are employees of Takeda and MO is a stockholder of Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}